Preclinical efficacy of MEK inhibition in Nras-mutant AML

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Oncogenic NRAS mutations are common in acute myeloid leukemia (AML).
• NRAS mutations are thought to cooperate with other genetic lesions in leukemogenesis.
• The independent prognostic value of NRAS mutations in AML is limited.

Purpose of the Study:

• To investigate the functional role of NRAS in AML.
• To evaluate the therapeutic potential of targeting NRAS signaling in AML.
• To assess the efficacy of MEK inhibitors in preclinical AML models.

Main Methods:

• Short hairpin RNA (shRNA)-mediated knockdown of NRAS in human AML cell lines and primary mouse leukemias.
• Conditional inactivation of a mutant Nras allele using the Mx1-Cre transgene in mice.
• Treatment of Nras(G12D) AML-transplanted mice with MEK inhibitors (PD0325901, trametinib) and a PI3K inhibitor (GDC-0941).

Main Results:

• AML cells with NRAS mutations demonstrated dependence on continuous oncogene expression.
• NRAS-deficient hematopoietic stem and progenitor cells (HSPCs) were functionally normal in adult mice.
• MEK inhibitors prolonged survival and reduced proliferation in Nras(G12D) AML models but did not induce apoptosis or differentiation.
• The PI3K inhibitor was ineffective alone and did not enhance MEK inhibitor activity.
• All treated mice eventually succumbed to progressive leukemia.

Conclusions:

• Oncogenic NRAS signaling is a validated therapeutic target in AML.
• MEK inhibitors show preclinical activity against NRAS-mutant AML.
• Combination regimens including MEK inhibitors warrant clinical investigation for AML treatment.